• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lantheus Holdings Inc. (Amendment)

    7/11/22 1:13:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    SC 13G/A 1 tv0003-lantheusholdingsinc.htm SCHEDULE 13G/A lantheusholdingsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 5)*

    Name of issuer:  Lantheus Holdings Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  516544103

    Date of Event Which Requires Filing of this Statement: June 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  516544103

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    111,971

    7.  SOLE DISPOSITIVE POWER

    7,270,243

    8.  SHARED DISPOSITIVE POWER

    168,481

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,438,724

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.84%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Lantheus Holdings Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    331 Treble Cove Road
    North Billerica, MA 01862

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    516544103

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  July 11, 2022

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $LNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    11/30/2022Outperform
    SVB Leerink
    More analyst ratings

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Niedzwiecki Daniel sold $472,440 worth of shares (6,000 units at $78.74), decreasing direct ownership by 6% to 87,057 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/17/25 4:31:48 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Mchugh Julie sold $423,771 worth of shares (5,192 units at $81.62), decreasing direct ownership by 17% to 25,962 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:33:01 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CFO and Treasurer Marshall Robert J. Jr. exercised 14,773 shares at a strike of $49.93 and sold $3,301,296 worth of shares (39,773 units at $83.00), decreasing direct ownership by 22% to 88,860 units (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

      6/11/25 4:32:44 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Lantheus Holdings with a new price target

      Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00

      12/18/24 7:37:47 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Redburn Atlantic initiated coverage on Lantheus Holdings with a new price target

      Redburn Atlantic initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $175.00

      9/3/24 8:07:35 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • JMP Securities reiterated coverage on Lantheus Holdings with a new price target

      JMP Securities reiterated coverage of Lantheus Holdings with a rating of Mkt Outperform and set a new price target of $130.00 from $100.00 previously

      7/10/24 3:24:56 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

      4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

      3/8/24 11:24:53 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    SEC Filings

    See more
    • SEC Form 144 filed by Lantheus Holdings Inc.

      144 - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/9/25 10:06:49 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

      SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

      6/6/25 11:59:42 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SD filed by Lantheus Holdings Inc.

      SD - Lantheus Holdings, Inc. (0001521036) (Filer)

      5/30/25 4:30:17 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    See more
    • PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

      BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

      6/2/25 8:00:00 AM ET
      $GEHC
      $LNTH
      Medical Electronics
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

      BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

      1/30/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus Appoints Julie Eastland as New Board Member

      BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors ("Board"), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent. "We are thrilled to welcome Julie Eastland t

      9/5/24 8:30:00 AM ET
      $DVAX
      $LNTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

      BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new data highlighting two oncology radiodiagnostic agents will be presented at the upcoming 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, taking place June 21-24, 2025, in New Orleans, LA. Presentation details are as follows: Oral Presentations Date & Time: Tuesday, June 24, 2025; 2:30 – 3:35 PM CTSession Number: SS39Session Title: Advancing Radiopharmaceutical Production, Qu

      6/11/25 4:01:00 PM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Present at the 2025 Truist Securities MedTech Conference

      BEDFORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the 2025 Truist Securities MedTech Conference at 8:40 a.m. ET on Tuesday, June 17. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus Lantheus is the leading

      6/10/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

      BEDFORD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 at 2:40 p.m. ET on Tuesday, June 10. To access a live webcast of the presentation, please visit the Investors section of the Company's website at www.lantheus.com. A replay of the webcast will be available on the Company's website for at least 30 days following the live presentation. About Lantheus Lanthe

      6/3/25 8:30:00 AM ET
      $LNTH
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care